Altimmune, Inc.
ALT · NASDAQ
Market closed$2.87$0.020000 (+0.70%)After hours $2.93 · +2.12%
Key statistics
Previous close$2.85
Open$2.79
Day high$2.95
Day low$2.77
52-week high$6.44
52-week low$2.56
Market cap253.30M
Volume2.96M
Average volume4.42M
P/E ratio-3.09
Forward P/E—
EPS-0.93
Dividend yield0.00%
Market context
Why it moved
ALT edged modestly higher amid a broader but contained market pullback, with the stock's slight gain likely driven by speculative buying interest in the biotech sector, buoyed by positive momentum seen in peer names like Sionna Therapeutics.
What is happening
Recent company-specific developments and publisher coverage.
Seeking Alpha · July 7, 2026Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade (ALT)Investing.com · June 22, 2026Leerink initiates Altimmune stock coverage citing liver drug dataThe Business Journals · June 17, 2026Altimmune moving headquarters from Gaithersburg to New JerseySimply Wall Street · May 19, 2026Several Insiders Invested In Altimmune Flagging Positive NewsStock Titan · May 13, 2026Biotech Altimmune banks $535M, plans Phase 3 liver trialThe Clinical Trial Vanguard · April 24, 2026Altimmune’s Remarkable $225M Offering Sees Surging DemandStocktwits · April 23, 2026ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’Stock Titan · April 22, 2026Altimmune seeks Phase 3 liver trial funds in stock sale Mt Newswire · June 22, 2026Leerink Partners Initiates Altimmune at Outperform With $10 Price Target Mt Newswire · June 17, 2026Altimmune Plans to Move Headquarters to New Jersey Mt Newswire · May 28, 2026Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients Mt Newswire · May 27, 2026Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease Benzinga · May 27, 2026Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis. Benzinga · May 18, 2026HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20 Benzinga · May 14, 2026Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11 Benzinga · May 13, 2026Altimmune Q1 2026 Earnings Call: Complete Transcript